GSK plc GSK announced that the FDA has approved its blockbuster respiratory drug, Nucala (mepolizumab), for a fifth ...

Gilead Sciences is a dominant player in the HIV market with market-leading treatments. HIV drug sales accounted for 69% of ...

PARKERSBURG, W.Va. (WTAP) - Urologists diagnose and treat diseases of the urinary tract in both men and women. They also ...

A widely available drug for urinary tract infections has never been formally approved by the US government. It’s not the only ...

Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period.

A kidney stone can be as small as a grain of sand- or as large as a golf ball! Staying hydrated can stop them from forming. Go to source). Due to the heat, the body loses more water through ...

Implications for the Future of UTI Care The approval of Blujepa represents a significant advance in the ongoing battle against urinary tract infections, particularly at a time when antimicrobial ...

whereas localized low-dose hormone therapy results in improvements in genitourinary symptoms and urinary tract infections. New findings from the study include the fact that premenopausal women ...

Urinary tract infections (UTIs) are bacterial infections of the urinary ... has made this class of antibiotics less useful for UTI treatment in recent years. Blujepa (gepotidacin) is the first drug ...

The new class of targeted, oral antibiotic for urinary tract infections is designed to bypass ... will be sold under the brand name Blujepa and is expected to be available in the second half ...

In March 2025, the drug received FDA approval under the brand name Blujepa for the treatment of females aged 12 years and older and weighing 40kg or more with uncomplicated urinary tract infections ...